EC Number   |
Disease |
PubMed ID |
Title of Publication  |
Category |
Confidence Level |
|---|
    3.5.3.1 | Carcinoma |
9719479 |
Alpha-difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells. |
diagnostic usage
ongoing research
therapeutic application
unassigned |
1
4
1
0 |
| 3.5.3.1 | Neoplasms |
8947521 |
Alteration in IL-1 and arginase activity of tumor-associated macrophages: a role in the promotion of tumor growth. |
causal interaction
ongoing research
unassigned |
4
1
0 |
| 3.5.3.1 | Insulin Resistance |
31622373 |
Alteration of adipose tissue immune cell milieu towards the suppression of inflammation in high fat diet fed mice by flaxseed oil supplementation. |
ongoing research
therapeutic application
unassigned |
4
1
0 |
| 3.5.3.1 | Ischemic Stroke |
30112629 |
Alteration of microRNA 340-5p and Arginase-1 Expression in Peripheral Blood Cells during Acute Ischemic Stroke. |
causal interaction
diagnostic usage
ongoing research
unassigned |
1
3
4
0 |
| 3.5.3.1 | Stroke |
30112629 |
Alteration of microRNA 340-5p and Arginase-1 Expression in Peripheral Blood Cells during Acute Ischemic Stroke. |
causal interaction
diagnostic usage
ongoing research
unassigned |
1
3
4
0 |
| 3.5.3.1 | Infertility |
30581349 |
Alterations in Arginase-NO-synthase System of Spermatozoa in Human Subjects with Different Fertility Potential. |
diagnostic usage
ongoing research
unassigned |
4
4
0 |
| 3.5.3.1 | Breast Neoplasms |
30514398 |
Alterations in arginine and energy metabolism, structural and signalling lipids in metastatic breast cancer in mice detected in plasma by targeted metabolomics and lipidomics. |
causal interaction
ongoing research
therapeutic application
unassigned |
3
1
1
0 |
| 3.5.3.1 | Neoplasm Metastasis |
30514398 |
Alterations in arginine and energy metabolism, structural and signalling lipids in metastatic breast cancer in mice detected in plasma by targeted metabolomics and lipidomics. |
causal interaction
ongoing research
therapeutic application
unassigned |
3
1
1
0 |
| 3.5.3.1 | Cardiovascular Diseases |
28704931 |
Alterations in Circulating Amino Acid Metabolite Ratio Associated with Arginase Activity Are Potential Indicators of Metabolic Syndrome: The Korean Genome and Epidemiology Study. |
causal interaction
diagnostic usage
ongoing research
unassigned |
1
3
2
0 |
| 3.5.3.1 | Metabolic Syndrome |
28704931 |
Alterations in Circulating Amino Acid Metabolite Ratio Associated with Arginase Activity Are Potential Indicators of Metabolic Syndrome: The Korean Genome and Epidemiology Study. |
causal interaction
diagnostic usage
ongoing research
unassigned |
1
3
2
0 |
| 3.5.3.1 | Neoplasms |
13746236 |
Alterations in morphology, arginase, and beta-glucuronidase within a clone of mouse tumor cells in vitro. |
ongoing research
unassigned |
3
0 |
| 3.5.3.1 | Cholestasis |
2889412 |
Alterations in selected serum biochemical constituents in equids after induced hepatic disease. |
diagnostic usage
ongoing research
unassigned |
2
3
0 |
| 3.5.3.1 | Amyotrophic Lateral Sclerosis |
1983181 |
Alterations of arginase activity in scrapie-infected mice and in amyotrophic lateral sclerosis. |
diagnostic usage
ongoing research
unassigned |
4
4
0 |
| 3.5.3.1 | Scrapie |
1983181 |
Alterations of arginase activity in scrapie-infected mice and in amyotrophic lateral sclerosis. |
diagnostic usage
ongoing research
unassigned |
4
4
0 |
| 3.5.3.1 | Asthma |
18635886 |
Alterations of the arginine metabolome in asthma. |
diagnostic usage
ongoing research
unassigned |
2
1
0 |
| 3.5.3.1 | COVID-19 |
34088793 |
Altered amino acid profile in patients with SARS-CoV-2 infection. |
causal interaction
diagnostic usage
unassigned |
2
1
0 |
| 3.5.3.1 | Prostatic Neoplasms |
30364895 |
Altered Cd8+ T lymphocyte Response Triggered by Arginase 1: Implication for Fatigue Intensification during Localized Radiation Therapy in Prostate Cancer Patients. |
diagnostic usage
therapeutic application
unassigned |
1
4
0 |
| 3.5.3.1 | Neoplasms |
2601556 |
Altered ornithine metabolism in tumor-bearing mice. |
unassigned |
0 |
| 3.5.3.1 | Infections |
28915996 |
Alternative strategy for visceral leishmaniosis control: HisAK70-Salmonella Choleraesuis-pulsed dendritic cells. |
unassigned |
0 |
| 3.5.3.1 | Infections |
19456233 |
Alternatively activated and immunoregulatory monocytes in human filarial infections. |
diagnostic usage
ongoing research
unassigned |
1
4
0 |
| 3.5.3.1 | Melanoma |
20463604 |
Alternatively activated macrophage possess antitumor cytotoxicity that is induced by IL-4 and mediated by arginase-1. |
unassigned |
0 |
| 3.5.3.1 | Neoplasms |
20463604 |
Alternatively activated macrophage possess antitumor cytotoxicity that is induced by IL-4 and mediated by arginase-1. |
unassigned |
0 |
| 3.5.3.1 | Alzheimer Disease |
33811757 |
Alzheimer's disease as a chronic maladaptive polyamine stress response. |
causal interaction
therapeutic application
unassigned |
3
4
0 |
| 3.5.3.1 | Dementia |
33811757 |
Alzheimer's disease as a chronic maladaptive polyamine stress response. |
causal interaction
therapeutic application
unassigned |
3
4
0 |
| 3.5.3.1 | Neoplasms |
33510635 |
Amino Acid Degrading Enzymes and Autophagy in Cancer Therapy. |
causal interaction
therapeutic application
unassigned |
4
4
0 |
| 3.5.3.1 | Autoimmune Diseases |
30797943 |
Amino acid metabolism as drug target in autoimmune diseases. |
ongoing research
unassigned |
2
0 |
| 3.5.3.1 | Diabetes Mellitus, Type 2 |
27190086 |
Amino acid metabolism reflecting arginase activity is increased in patients with type 2 diabetes and associated with endothelial dysfunction. |
causal interaction
diagnostic usage
ongoing research
unassigned |
4
3
2
0 |
| 3.5.3.1 | arginase deficiency |
19052914 |
Amino acids in CSF and plasma in hyperammonaemic coma due to arginase1 deficiency. |
causal interaction
unassigned |
4
0 |
| 3.5.3.1 | Coma |
19052914 |
Amino acids in CSF and plasma in hyperammonaemic coma due to arginase1 deficiency. |
causal interaction
unassigned |
4
0 |
| 3.5.3.1 | argininosuccinate lyase deficiency |
23324524 |
Ammonia Control in Children Ages 2 Months through 5 Years with Urea Cycle Disorders: Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate. |
diagnostic usage
unassigned |
2
0 |
| 3.5.3.1 | argininosuccinate synthase deficiency |
23324524 |
Ammonia Control in Children Ages 2 Months through 5 Years with Urea Cycle Disorders: Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate. |
diagnostic usage
unassigned |
2
0 |
| 3.5.3.1 | Argininosuccinic Aciduria |
23324524 |
Ammonia Control in Children Ages 2 Months through 5 Years with Urea Cycle Disorders: Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate. |
diagnostic usage
unassigned |
2
0 |
| 3.5.3.1 | Citrullinemia |
23324524 |
Ammonia Control in Children Ages 2 Months through 5 Years with Urea Cycle Disorders: Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate. |
diagnostic usage
unassigned |
2
0 |
| 3.5.3.1 | ornithine carbamoyltransferase deficiency |
23324524 |
Ammonia Control in Children Ages 2 Months through 5 Years with Urea Cycle Disorders: Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate. |
diagnostic usage
unassigned |
2
0 |
| 3.5.3.1 | Ornithine Carbamoyltransferase Deficiency Disease |
23324524 |
Ammonia Control in Children Ages 2 Months through 5 Years with Urea Cycle Disorders: Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate. |
diagnostic usage
unassigned |
2
0 |
| 3.5.3.1 | pantoate-beta-alanine ligase (amp-forming) deficiency |
23324524 |
Ammonia Control in Children Ages 2 Months through 5 Years with Urea Cycle Disorders: Comparison of Sodium Phenylbutyrate and Glycerol Phenylbutyrate. |
diagnostic usage
unassigned |
2
0 |
| 3.5.3.1 | Herpes Simplex |
22222510 |
Amniotic Membrane Induces Peroxisome Proliferator-Activated Receptor-? Positive Alternatively Activated Macrophages. |
unassigned |
0 |
| 3.5.3.1 | Anemia, Sickle Cell |
17353439 |
Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. |
causal interaction
therapeutic application
unassigned |
4
4
0 |
| 3.5.3.1 | Bronchopulmonary Dysplasia |
27895230 |
An arginase-1 SNP that protects against the development of pulmonary hypertension in bronchopulmonary dysplasia enhances NO-mediated apoptosis in lymphocytes. |
causal interaction
diagnostic usage
therapeutic application
unassigned |
2
3
3
0 |
| 3.5.3.1 | Hypertension, Pulmonary |
27895230 |
An arginase-1 SNP that protects against the development of pulmonary hypertension in bronchopulmonary dysplasia enhances NO-mediated apoptosis in lymphocytes. |
causal interaction
diagnostic usage
therapeutic application
unassigned |
2
3
3
0 |
| 3.5.3.1 | Starvation |
31666335 |
An arginase-based system for selection of transfected CHO cells without the use of toxic chemicals. |
ongoing research
unassigned |
4
0 |
| 3.5.3.1 | Infections |
18056391 |
An effect of parasite-encoded arginase on the outcome of murine cutaneous leishmaniasis. |
causal interaction
ongoing research
unassigned |
1
2
0 |
| 3.5.3.1 | Leishmaniasis, Cutaneous |
18056391 |
An effect of parasite-encoded arginase on the outcome of murine cutaneous leishmaniasis. |
causal interaction
ongoing research
unassigned |
1
2
0 |
| 3.5.3.1 | Carcinoma, Hepatocellular |
23737831 |
An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo. |
ongoing research
therapeutic application
unassigned |
2
1
0 |
| 3.5.3.1 | Melanoma |
23737831 |
An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo. |
ongoing research
therapeutic application
unassigned |
2
1
0 |
| 3.5.3.1 | Neoplasms |
23737831 |
An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo. |
ongoing research
therapeutic application
unassigned |
2
1
0 |
| 3.5.3.1 | Hypercholesterolemia |
24612630 |
An Increased Arginase Activity Is Associated with Corpus Cavernosum Impairment Induced by Hypercholesterolemia. |
causal interaction
unassigned |
4
0 |
| 3.5.3.1 | Neoplasms |
33524560 |
An injectable hydrogel using an immunomodulating gelator for amplified tumor immunotherapy by blocking the arginase pathway. |
unassigned |
0 |
| 3.5.3.1 | Neoplasms |
26278104 |
An orthotopic xenograft model with survival hindlimb amputation allows investigation of the effect of tumor microenvironment on sarcoma metastasis. |
unassigned |
0 |
| 3.5.3.1 | Infections |
31175971 |
An overview of the immune response and Arginase I on CHIKV immunopathogenesis. |
causal interaction
unassigned |
4
0 |
| 3.5.3.1 | arginase deficiency |
11746885 |
Analysis of amino acids as formamidene butyl esters by electrospray ionization tandem mass spectrometry. |
diagnostic usage
unassigned |
1
0 |
| 3.5.3.1 | Hyperargininemia |
11746885 |
Analysis of amino acids as formamidene butyl esters by electrospray ionization tandem mass spectrometry. |
diagnostic usage
unassigned |
1
0 |
| 3.5.3.1 | Neoplasms |
31084559 |
Analysis of Macrophage Activation Markers in an Experimental Model of Cutaneous Leishmaniasis Treated with Photodynamic Therapy Mediated by 5-Aminolevulinic Acid. |
causal interaction
diagnostic usage
unassigned |
1
1
0 |
| 3.5.3.1 | Hyperargininemia |
22959135 |
Analysis of novel ARG1 mutations causing hyperargininemia and correlation with arginase I activity in erythrocytes. |
causal interaction
unassigned |
3
0 |
| 3.5.3.1 | Prostatic Neoplasms |
20711410 |
Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer. |
causal interaction
diagnostic usage
ongoing research
unassigned |
1
3
3
0 |
| 3.5.3.1 | arginase deficiency |
18950360 |
Anesthesia in a patient with arginase deficiency: implications and management. |
causal interaction
therapeutic application
unassigned |
3
2
0 |
| 3.5.3.1 | Hyperargininemia |
18950360 |
Anesthesia in a patient with arginase deficiency: implications and management. |
causal interaction
therapeutic application
unassigned |
3
2
0 |
| 3.5.3.1 | arginase deficiency |
25611620 |
Anesthetic management of a patient with arginase deficiency undergoing liver transplantation. |
therapeutic application
unassigned |
1
0 |
| 3.5.3.1 | Hyperargininemia |
25611620 |
Anesthetic management of a patient with arginase deficiency undergoing liver transplantation. |
therapeutic application
unassigned |
1
0 |
| 3.5.3.1 | Urea Cycle Disorders, Inborn |
25611620 |
Anesthetic management of a patient with arginase deficiency undergoing liver transplantation. |
therapeutic application
unassigned |
1
0 |
| 3.5.3.1 | arginase deficiency |
32025996 |
Anesthetic management of a pediatric patient with arginase-1 deficiency undergoing strabismus operation: a case report. |
causal interaction
therapeutic application
unassigned |
4
1
0 |
| 3.5.3.1 | Hyperargininemia |
32025996 |
Anesthetic management of a pediatric patient with arginase-1 deficiency undergoing strabismus operation: a case report. |
causal interaction
therapeutic application
unassigned |
4
1
0 |
| 3.5.3.1 | Strabismus |
32025996 |
Anesthetic management of a pediatric patient with arginase-1 deficiency undergoing strabismus operation: a case report. |
causal interaction
therapeutic application
unassigned |
4
1
0 |
| 3.5.3.1 | Urea Cycle Disorders, Inborn |
32025996 |
Anesthetic management of a pediatric patient with arginase-1 deficiency undergoing strabismus operation: a case report. |
causal interaction
therapeutic application
unassigned |
4
1
0 |
| 3.5.3.1 | Cardiovascular Diseases |
25446432 |
Angiotensin II limits NO production by upregulating arginase through a p38 MAPK-ATF-2 pathway. |
causal interaction
unassigned |
4
0 |
| 3.5.3.1 | Cardiovascular Diseases |
25807386 |
Angiotensin II-induced arterial thickening, fibrosis and stiffening involves elevated arginase function. |
unassigned |
0 |
| 3.5.3.1 | Cardiovascular Diseases |
21289285 |
Angiotensin II-induced Vascular Endothelial Dysfunction through RhoA/Rho Kinase/p38 Mitogen-Activated Protein Kinase/Arginase Pathway. |
causal interaction
unassigned |
4
0 |
| 3.5.3.1 | Hepatitis, Autoimmune |
11750286 |
Anti-CYP2D6 antibodies detected by quantitative radioligand assay and relation to antibodies to liver-specific arginase in patients with autoimmune hepatitis. |
diagnostic usage
ongoing research
unassigned |
4
2
0 |
| 3.5.3.1 | Asthma |
22915279 |
Anti-inflammatory Effect of Arginase Inhibitor and Corticosteroid on Airway Allergic Reactions in a Dermatophogoides farinae-induced NC/Nga Mouse Model. |
ongoing research
therapeutic application
unassigned |
3
3
0 |
| 3.5.3.1 | Hypersensitivity |
22915279 |
Anti-inflammatory Effect of Arginase Inhibitor and Corticosteroid on Airway Allergic Reactions in a Dermatophogoides farinae-induced NC/Nga Mouse Model. |
ongoing research
therapeutic application
unassigned |
3
3
0 |
| 3.5.3.1 | Neoplasms |
28904063 |
Anti-Jagged immunotherapy inhibits MDSCs and overcomes tumor-induced tolerance. |
unassigned |
0 |
| 3.5.3.1 | Leukemia, T-Cell |
22926702 |
Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
1
1
3
2 |
| 3.5.3.1 | Infections |
9413508 |
Anti-MHV3 state induced by IFN gamma in macrophages is not related to arginine metabolism. |
ongoing research
unassigned |
3
0 |
| 3.5.3.1 | Carcinoma, Hepatocellular |
22873218 |
Anti-tumor Efficacy of a Recombinant Human Arginase in Human Hepatocellular Carcinoma. |
ongoing research
therapeutic application
unassigned |
4
4
0 |
| 3.5.3.1 | Neoplasms |
22873218 |
Anti-tumor Efficacy of a Recombinant Human Arginase in Human Hepatocellular Carcinoma. |
ongoing research
therapeutic application
unassigned |
4
4
0 |
| 3.5.3.1 | Breast Neoplasms |
27066094 |
Antitumor Effect of IP-10 by Using Two Different Approaches: Live Delivery System and Gene Therapy. |
causal interaction
ongoing research
therapeutic application
unassigned |
4
1
2
0 |
| 3.5.3.1 | Neoplasms |
27066094 |
Antitumor Effect of IP-10 by Using Two Different Approaches: Live Delivery System and Gene Therapy. |
causal interaction
ongoing research
therapeutic application
unassigned |
4
1
2
0 |
| 3.5.3.1 | Prostatic Neoplasms |
18759245 |
Apoptosis-inducing high (.)NO concentrations are not sustained either in nascent or in developed cancers. |
causal interaction
diagnostic usage
unassigned |
3
3
0 |
| 3.5.3.1 | Neoplasms |
30613266 |
Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages. |
causal interaction
therapeutic application
unassigned |
3
2
0 |
| 3.5.3.1 | Neoplasms |
33807310 |
ARG1 mRNA Level Is a Promising Prognostic Marker in Head and Neck Squamous Cell Carcinomas. |
unassigned |
0 |
| 3.5.3.1 | Atherosclerosis |
25484082 |
ARG2 impairs endothelial autophagy through regulation of MTOR and PRKAA/AMPK signaling in advanced atherosclerosis. |
causal interaction
therapeutic application
unassigned |
3
1
0 |
| 3.5.3.1 | COVID-19 |
33806290 |
Arginase 1 (Arg1) as an Up-Regulated Gene in COVID-19 Patients: A Promising Marker in COVID-19 Immunopathy. |
diagnostic usage
therapeutic application
unassigned |
1
1
0 |
| 3.5.3.1 | Asthma |
25789453 |
Arginase 1 activity worsens lung-protective immunity against Streptococcus pneumoniae infection. |
causal interaction
therapeutic application
unassigned |
4
1
0 |
| 3.5.3.1 | Infections |
25789453 |
Arginase 1 activity worsens lung-protective immunity against Streptococcus pneumoniae infection. |
causal interaction
therapeutic application
unassigned |
4
1
0 |
| 3.5.3.1 | Pneumococcal Infections |
25789453 |
Arginase 1 activity worsens lung-protective immunity against Streptococcus pneumoniae infection. |
causal interaction
therapeutic application
unassigned |
4
1
0 |
| 3.5.3.1 | Airway Obstruction |
20124949 |
Arginase 1 and arginase 2 variations associate with asthma, asthma severity and beta2 agonist and steroid response. |
causal interaction
ongoing research
therapeutic application
unassigned |
4
2
1
0 |
| 3.5.3.1 | Asthma |
20124949 |
Arginase 1 and arginase 2 variations associate with asthma, asthma severity and beta2 agonist and steroid response. |
causal interaction
ongoing research
therapeutic application
unassigned |
4
2
1
0 |
| 3.5.3.1 | Diabetes Mellitus |
21217072 |
Arginase 1 contributes to diminished coronary arteriolar dilation in patients with diabetes. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
1
3
2
1 |
| 3.5.3.1 | Asthma |
29183288 |
Arginase 1 deletion in myeloid cells affects the inflammatory response in allergic asthma, but not lung mechanics, in female mice. |
causal interaction
ongoing research
therapeutic application
unassigned |
2
3
2
0 |
| 3.5.3.1 | Pneumonia |
29183288 |
Arginase 1 deletion in myeloid cells affects the inflammatory response in allergic asthma, but not lung mechanics, in female mice. |
causal interaction
ongoing research
therapeutic application
unassigned |
2
3
2
0 |
| 3.5.3.1 | Amyloidosis |
33519806 |
Arginase 1 Insufficiency Precipitates Amyloid-? Deposition and Hastens Behavioral Impairment in a Mouse Model of Amyloidosis. |
unassigned |
0 |
| 3.5.3.1 | Pneumonia |
27043409 |
Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation. |
ongoing research
therapeutic application
unassigned |
4
1
0 |
| 3.5.3.1 | Dacryocystitis |
32780506 |
Arginase 1 is involved in lacrimal hyposecretion in male NOD mice, a model of Sjögren's syndrome, regardless of dacryoadenitis status. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
1
2
2
1 |
| 3.5.3.1 | Myocardial Infarction |
34237174 |
Arginase 1 is upregulated at admission in patients with ST-elevation myocardial infarction. |
causal interaction
diagnostic usage
ongoing research
unassigned |
2
4
2
0 |
| 3.5.3.1 | ST Elevation Myocardial Infarction |
34237174 |
Arginase 1 is upregulated at admission in patients with ST-elevation myocardial infarction. |
causal interaction
diagnostic usage
ongoing research
unassigned |
2
4
2
0 |
| 3.5.3.1 | Hypertension |
23908657 |
Arginase 1 mediates increased blood pressure and contributes to vascular endothelial dysfunction in deoxycorticosterone acetate-salt hypertension. |
ongoing research
therapeutic application
unassigned |
4
1
0 |
| 3.5.3.1 | Psoriasis |
12507903 |
Arginase 1 overexpression in psoriasis: limitation of inducible nitric oxide synthase activity as a molecular mechanism for keratinocyte hyperproliferation. |
diagnostic usage
unassigned |
3
0 |
| 3.5.3.1 | Pemphigus |
33528891 |
Arginase 1+ IL-10+ polymorphonuclear myeloid-derived suppressor cells are elevated in patients with active pemphigus and correlate with an increased Th2/Th1 response. |
causal interaction
unassigned |
3
0 |
| 3.5.3.1 | Neuroinflammatory Diseases |
26538310 |
Arginase 1+ microglia reduce A? plaque deposition during IL-1?-dependent neuroinflammation. |
therapeutic application
unassigned |
1
0 |
| 3.5.3.1 | Fatty Liver |
25678387 |
Arginase 1: a potential marker of a common pattern of liver steatosis in HCV and NAFLD children. |
causal interaction
unassigned |
2
0 |
